All News

A federal pricing pact with Pfizer and an executive order on pediatric cancer AI may reshape affordability and evidence pathways for pharmacists and patients.

Explore the booming online pharmacy market for vitamins and supplements, and discover how pharmacists can guide patients in this digital landscape.

BATURA demonstrated that albuterol/budesonide significantly reduced severe exacerbation risk reduction in patients with mild asthma.

Remibrutinib gains FDA approval as the first oral treatment for chronic hives, offering hope for patients unresponsive to standard therapies.

Umoja Biopharma's UB-VV111 gains FDA fast track designation, revolutionizing CAR T-cell therapy for relapsed lymphoma and leukemia patients.

Cevostamab shows promise as a post-CAR T therapy for relapsed/refractory multiple myeloma, enhancing MRD-negative responses and improving patient outcomes.

AMT-130 demonstrates meaningful reductions in disease progression in the rare and chronic Huntington disease.

Recent trials reveal fam-trastuzumab deruxtecan-nxki's potential to transform treatment for patients with high-risk HER2-positive breast cancer, enhancing survival rates significantly.

Pharmacists should ensure pneumococcal vaccination strategies are tailored to high-risk individuals, especially those with type 2 diabetes (T2D).

Pharmacists explore virtual solutions for opioid use disorder, enhancing treatment retention and accessibility while addressing economic impacts.

Pharmacists lead the charge in integrating pharmacogenetics into patient care, overcoming education barriers and enhancing treatment outcomes through expert guidance.

New research reveals that eggs do not raise bad cholesterol; instead, saturated fat in the diet is the real culprit for heart disease.

Recent FDA approval of nirsevimab and clesrovimab have transformed RSV prevention in infants, prompting new recommendations from the CDC and AAP and replacing the long-standing role of palivizumab.

Adam Kahleifeh, PharmD, BCOP, discusses the impact of IDH mutations in low-grade gliomas.

Mary Nauffal, PharmD, MS, BCOP, discusses innovative use of isatuximab for red cell aplasia post stem cell transplant, highlighting its potential in clinical trials.

Etentamig shows promise in managing infections for relapsed/refractory multiple myeloma.

Inclisiran, a small interfering RNA PCSK9 inhibitor, was effective and tolerable in real-world practice, though pharmacists must make important considerations for patients switching from another medicine.

The new formulation of intravenous immunoglobulin (IVIG) provides patients another option to help reduce the incidence of severe bacterial infections.

The event featured expert-led sessions, networking, and recognition for technicians’ outstanding contributions.

The FDA approves guselkumab, the first IL-23 inhibitor for pediatric psoriasis and psoriatic arthritis, enhancing treatment options for children.

Patients with newly diagnosed transplant-eligible multiple myeloma (NDTE-MM) had high rates of complete response and minimal residual disease–negativity.

A meta-analysis found that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce sustained reductions across lipid biomarkers, including low-density lipoprotein cholesterol (LDL-C).

Anitocabtagene autoleucel shows impressive efficacy and safety in treating relapsed/refractory multiple myeloma, achieving a 97% overall response rate.

Pharmacists play a crucial role in managing drug interactions and optimizing treatment with CDK4/6 inhibitors for HER2-positive breast cancer patients.

Biolinq Shine, a wearable biosensor, revolutionizes diabetes management with real-time glucose, activity, and sleep tracking.

Pediatric flu cases surge, revealing alarming rates of encephalopathy.

Xavier Leleu, MD, PhD, shares how OBI technology reduces preparation time and manual pushes for pharmacists.